

## Director/PDMR Shareholding

**March 7, 2014** - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified that Matthew Emmens, the Company’s Chairman, sold 36,375 Ordinary Shares in the Company (“Shares”) today at an average sale price of £32.8309. The Shares were sold on the London Stock Exchange.

Following the above transaction, Mr Emmens holds 20,399 Shares and 5,872 American Depositary Shares in the Company (“ADSs”). Each ADS represents three Shares.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie  
Deputy Company Secretary

## For further information please contact:

### Investor Relations

Laurie Stelzer	<a href="mailto:lstelzer@shire.com">lstelzer@shire.com</a>	+1 781 482 0733
Eric Rojas	<a href="mailto:erojas@shire.com">erojas@shire.com</a>	+1 781 482 0999
Sarah Elton-Farr	<a href="mailto:seltonfarr@shire.com">seltonfarr@shire.com</a>	+44 1256 894157

## Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

[www.shire.com](http://www.shire.com)